Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 with Concurrent Chemoradiotherapy in Locally Advanced Cervical Cancer
NCT07232654Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Nov 2025
- Primary completion
- Nov 2027
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of iparomlimab + tuvonralimab in Cervical Cancer (CC) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: 2-year Progression-Free Survival Rate. Started Nov 2025; status: recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT07232654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07232654.